Aspartyl(Asparaginyl)-Beta-Hydroxylase (ASPH) is a 2-oxoglutarate (2OG). ASPH catalyzes post-translational hydroxylation of critically positioned aspartic acids and asparagines in specific calcium-binding Epidermal Growth Factor (cbEGF) domains. Mutations in ASPH are linked with Traboulsi syndrome in humans, and a mouse knock-out demonstrates similar features. Hepatocellular carcinoma and pancreatic cancer are known to significantly over-express ASPH on the cell surface, conferring an aggressive, invasive phenotype. ASPH has been demonstrated to aberrantly activate the NOTCH signaling pathway, and cleaved ASPH is capable of suppressing NK cell activity. ASPH inhibitors have been rationally designed and synthesized, and demonstrate predicted activities in vitro, including suppression of migration, invasion, and NOTCH pathway related proteins. Experiments demonstrate significant suppression of tumor growth at 1mg/kg. These compounds have demonstrated context dependent Notch pathway inhibition in vivo.

Chair:

- Mathew Cherian, VP of Operations and R&D, ReVive Biotechnology, USA

Co-moderator:

- Qurrotul Aini Shodiquna, Head of Regulatory Affairs, PT Ibu Bumi Sejahtera, Indonesia

Panellist:

- Mark Olsen PhD, Associate Professor, Pharmaceutical Sciences, Mid-Western University, Glendale, Arizona, USA

17^th Congress of the European Association for Clinical Pharmacology and Therapeutics EACPT2025 will be held in Helsinki, Finland, in 28 June – 1 July, 2025. Within the congress theme, “Embracing Innovations for Optimized Patient Care,” the scientific program offers a cutting-edge exploration of clinical pharmacology and therapeutics, the latest in the research and drug development arena and an update of recent advances and emerging developments within therapeutics. Moreover, there will be ample opportunities for scientific discussions and networking during the poster and refreshment breaks, and various social events after the congress days. Please visit our congress website for more information. Note! Abstract submission deadline is on 20 February. 

Important dates

• Abstract submissions for oral presentations, posters and workshops open: August 2024
• Early bird registration opens: October 2024

The MyDispense Symposium will take place from 13th to 16th July 2025 at the Monash Prato Centre, Italy, marking the 15th anniversary of the MyDispense programme. This event will introduce MyDispense version 8.0, incorporating features such as Medication Administration Records (MAR), Pharmacist Independent Prescribing, and diagnostic tools for pharmacists. The upgrade also includes enhancements to ePharmacy workflows and patient avatars to improve the realism of training exercises.

The FIP Pharmacy Practice Research Special Interest Group (PPR SIG) is hosting an international event — “Pharmacy practice research summer meeting for PhD students, postdoctoral fellows and supervisors” — on 30 August 2025 in Copenhagen, Denmark.

The main scope of the PPR SIG is to increase pharmacy practice contributions to global health by providing greater access to the latest high-quality international pharmacy practice research. During this meeting both starting-out and experienced researchers will be able to collaborate on major PPR themes.

PhD students and their supervisors, researchers, academics, professional organisations and practitioners involved in research are welcome to join this face-to-face meeting to present their work and to start building new global pharmacy networks.

This one-day event, organized by the FIP Health and Medicines Information Section (HaMIS), will examine how health literacy can bridge gaps in care, empower patients, and elevate the pharmacy profession’s role in advancing health equity.